COVID-19 Scientific Webinar Series

The world faces an unprecedented and growing challenge with the COVID-19 pandemic. It is imperative that we accelerate therapeutics to patients for COVID-19 and also continue to advance programs to address other critical diseases with smarter, modern drug development.

Certara is working in close partnership with biopharma, government, nonprofits and others to progress COVID-19 therapeutics and others with clinical pharmacology and model-informed drug development approaches to support critical stage-gate decisions, development strategies, clinical trial designs, and dosing optimization.

Please join our complimentary COVID-19 Scientific Webinar Series to hear from leading experts on the latest topics in drug development from dosing for special populations to managing clinical studies and regulatory filings in this uncertain environment.

Title: Model-based meta-analysis for comparative efficacy and safety of therapeutics for COVID-19
Date: Check back soon for a new date
Jaap Mandema, PhD is Chief Innovation Officer at Certara

On-Demand Webinars

Title: Accelerating Therapeutics for COVID-19
Dr. Dan Hartman, Director of Integrated Development, Bill & Melinda Gates Foundation
Dr. Steven Kern, Deputy Director of Quantitative Sciences, Bill & Melinda Gates Foundation
Dr. Craig Rayner, President of Integrated Drug Development, Certara
Dr. Fran Brown, SVP of Integrated Drug Development, Certara

Title: Considerations for Management of Clinical Trials and Regulatory Filing Strategy in Light of COVID-19
Demetrius Carter, Senior Vice President, Services Operations, Regulatory Services, Synchrogenix, a Certara Company
Elaine B. Taylor, Vice President, Regulatory Strategy and Policy, Synchrogenix, a Certara Company

Title: COVID-19: Building for Today and Tomorrow – Therapeutic Considerations for Children and Pregnant Women
Dr. Jeff Barrett, Senior Advisor to the CEO at the Critical Path Institute
Dr. Patrick Smith, SVP of Integrated Drug Development Strategy, Certara
Dr. Karen Rowland Yeo, SVP, Client & Regulatory Strategy, Certara

Title: Model-informed Drug Repurposing - Applications for COVID-19
Colin Pillai, Founder at CP+ Associates GmbH and CEO at Pharmacometrics Africa NPC
Adeniyi Olagunju, Senior Lecturer, Wellcome Trust Fellow
Michael Dodds, Executive Director of Integrated Drug Development, Certara
Samer Mouksassi, Senior Director of Integrated Drug Development, Certara
Yuan Xiong, Director of Integrated Drug Development, Certara

Title: COVID-19 Response: New Opportunities & Implications for the Future of Drug Development in Emerging Economies
Edward Mills, PhD, FRCP Edin, Principal Scientist, Global Health, Cytel
Craig Rayner, PharmD. President, Integrated Drug Development, Certara
James Orbinski, Dignitas International and York University
Derek Angus, REMAP-CAP and Crown Coronation Trials, and University of Pittsburgh
Trevor Mundel, President, Global Health Division, Bill & Melinda Gates Foundation
Robin Mogg, Bill & Melinda Gates Medical Research Institute

Title: Mitigation Strategies for US and EU Supply Chain Risk Introduced by the COVID-19 Pandemic
Terrance (Terry) Ocheltree, Ph.D., R.Ph., Vice President, Regulatory Strategy and CMC, Certara
James Zoshak, Associate Principal Regulatory Writer, Certara
Renata Lavach-Savy, Associate Principal Regulatory Writer, Certara
Robert Waterland, Ph.D., Associate Principal Regulatory Writer, Certara

Title: HIV Déjà Vu? Optimizing Cocktail Therapies for COVID-19
     Edward Mills, PhD, Vice President of Real World Evidence and Senior Principal Scientist at Cytel
     Michael Dodds, PhD, Executive Director Integrated Drug Development at Certara
     Suzanne Minton, PhD, Director of Content Strategy at Certara
     Rajesh Krishna, PhD, Senior Director, Clinical Pharmacology at Certara

Title: Accelerating Vaccine Development: Applications to COVID-19 and Future Pandemics?
     Thomas Kerbusch, Chief Growth Officer, Certara
     Amy Cheung, Senior Director, Integrated Drug Development, Certara
     Piet van der Graaf, Senior Vice President, Quantitative Systems Pharmacology, Certara
     Jos Lommerse, Director, Integrated Drug Development, Certara

Click Here to View the Recording

Title: Exploring the Effect of COVID-19 on HTA Bodies Now and in the Future
Iñaki Gutiérrez Ibarluzea, Director of Innovation, Basque Foundation for Health Innovation and Research (BIOEF)
Michelle Mujoomdar, Director, Scientific Affairs, Canadian Agency for Drugs and Technologies in Health (CADTH)
Lou Garrison, Professor, Departments of Pharmacy, Global Health and Health Services, University of Washington
Matthew Broughman, Senior Global Consultant, Certara Evidence and Access

Recording Coming Soon!

Follow Us:

Additional text can go here...